Amyloid Plaques

The FDA’s decision to approve Aduhelm represented one of the agency’s “most controversial [approvals] ever,” according to a piece published in the Ideas and Opinions section of Annals of Internal Medicine.

Donanemab, an investigational antibody that targets a modified form of beta amyloid, yielded “modestly less” cognitive and functional decline than placebo among patients with early symptomatic Alzheimer’s disease in a phase 2 trial.

Donanemab, an investigational antibody that targets a modified form of beta amyloid, significantly slowed decline on a composite measure of cognition and daily function in early Alzheimer's disease, according to a press release.